📣 VC round data is live. Check it out!
- Public Comps
- Staar Surgical
Staar Surgical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Staar Surgical and similar public comparables like Anbio Biotechnology, Vitrolife, Nihon Kohden, Poly Medicure and more.
Staar Surgical Overview
About Staar Surgical
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Founded
1982
HQ

Employees
1.2K
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialStaar Surgical Financials
Staar Surgical reported last 12-month revenue of $278M and EBITDA of $19M.
In the same LTM period, Staar Surgical generated $210M in gross profit, $19M in EBITDA, and had net loss of ($42M).
Revenue (LTM)
Staar Surgical P&L
In the most recent fiscal year, Staar Surgical reported revenue of $332M and EBITDA of $54M.
Staar Surgical is profitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 16%, and net margin of 3%.
Financial data powered by Morningstar, Inc.
Staar Surgical Stock Performance
Staar Surgical has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Staar Surgical's stock price is $28.49.
Staar Surgical share price decreased by 4.7% in the last 30 days, and increased by 69.8% in the last year.
Staar Surgical has an EPS (earnings per share) of $0.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -3.6% | -4.7% | 52.4% | 69.8% | $0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStaar Surgical Valuation Multiples
Staar Surgical trades at 4.6x EV/Revenue multiple, and 67.3x EV/EBITDA.
EV / Revenue (LTM)
Staar Surgical Financial Valuation Multiples
As of June 3, 2026, Staar Surgical has market cap of $1B and EV of $1B.
Staar Surgical has a P/E ratio of (33.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Staar Surgical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Staar Surgical Margins & Growth Rates
Staar Surgical grew revenue by 8% and EBITDA by 25% in the last fiscal year.
In the most recent fiscal year, Staar Surgical reported gross margin of 55%, EBITDA margin of 16%, and net margin of 3%.
Staar Surgical Margins
Staar Surgical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Staar Surgical Operational KPIs
Staar Surgical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Staar Surgical's Rule of 40 is (16%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Staar Surgical's Rule of X is (16%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Staar Surgical Competitors
Staar Surgical competitors include Anbio Biotechnology, Vitrolife, Nihon Kohden, Poly Medicure, Nolato, SKAN Group, Haier Biomedical, Savaria, El.En. Group and VCANBIO.
Most Staar Surgical public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 162.7x | - | 244.0x | - | |||
| 3.9x | 3.9x | 13.4x | 13.1x | |||
| 0.9x | 0.9x | 7.8x | 8.1x | |||
| 6.8x | 6.6x | 22.9x | 27.5x | |||
| 1.4x | 1.4x | 8.5x | 8.5x | |||
| 3.5x | 3.3x | 30.5x | 25.9x | |||
| 3.6x | 3.5x | 21.3x | 21.2x | |||
| 2.4x | 2.3x | 11.6x | 11.2x | |||
This data is available for Pro users. Sign up to see all Staar Surgical competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Staar Surgical
| When was Staar Surgical founded? | Staar Surgical was founded in 1982. |
| Where is Staar Surgical headquartered? | Staar Surgical is headquartered in United States. |
| How many employees does Staar Surgical have? | As of today, Staar Surgical has over 1K employees. |
| Who is the CEO of Staar Surgical? | Staar Surgical's CEO is Deborah Andrews. |
| Is Staar Surgical publicly listed? | Yes, Staar Surgical is a public company listed on Nasdaq. |
| What is the stock symbol of Staar Surgical? | Staar Surgical trades under STAA ticker. |
| When did Staar Surgical go public? | Staar Surgical went public in 1983. |
| Who are competitors of Staar Surgical? | Staar Surgical main competitors include Anbio Biotechnology, Vitrolife, Nihon Kohden, Poly Medicure, Nolato, SKAN Group, Haier Biomedical, Savaria, El.En. Group, VCANBIO. |
| What is the current market cap of Staar Surgical? | Staar Surgical's current market cap is $1B. |
| What is the current revenue of Staar Surgical? | Staar Surgical's last 12 months revenue is $278M. |
| What is the current revenue growth of Staar Surgical? | Staar Surgical revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Staar Surgical? | Current revenue multiple of Staar Surgical is 4.6x. |
| What is the current EBITDA of Staar Surgical? | Staar Surgical's last 12 months EBITDA is $19M. |
| What is Staar Surgical's EBITDA margin? | Staar Surgical's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Staar Surgical? | Current EBITDA multiple of Staar Surgical is 67.3x. |
| What is the current FCF of Staar Surgical? | Staar Surgical's last 12 months FCF is ($3M). |
| What is Staar Surgical's FCF margin? | Staar Surgical's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Staar Surgical? | Current FCF multiple of Staar Surgical is (381.1x). |
| How many companies Staar Surgical has acquired to date? | Staar Surgical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Staar Surgical has invested to date? | Staar Surgical hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Staar Surgical
Lists including Staar Surgical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.